Subclinical alterations in coagulation and fibrinolysis in patients undergoing autologous peripheral blood stem cell transplantation.
We monitored 30 laboratory hemostatic parameters in an attempt to better comprehend alterations in coagulation and fibrinolysis in 10 patients with hematological malignancies subjected to autologous peripheral blood stem cell transplantation (APBSCT). These parameters were assessed before and just after high-dose conditioning chemotherapy, on days 1, 7, 14 and 28. Although, clinical manifestations associated with fibrino-coagulation disorders never occurred, including veno-occlusive disease, a statistically significant increase was seen in 7 of 30 parameters, compared to values seen before conditioning chemotherapy. These were subdivided into early and late phase parameters. The early phase parameters, which increased during the first day after the conditioning chemotherapy was given, then returned to baseline values, included protein C, plasma tissue factor and tissue-plasminogen activator. The late phase parameters, which increased over baseline values during days 7 to 28, included free-protein S, fibrinogen, plasmin-alpha2-plasmin inhibitor complex and soluble-thrombomodulin. The increase of early phase parameters, as produced by the liver and by endothelial cells, may reflect tissue damage by conditioning chemotherapy. Late phase parameters increased in parallel with C-reactive protein, which suggests a correlation with the degree of inflammation, such as the presence of infective disease during neutropenia. These subclinical alterations in coagulation and fibrinolysis which take on a biphasic pattern during the course of APBSCT should be kept in mind by the attending physicians during therapy.
Notoya
A
A
Department of Medicine II, Hokkaido University School of Medicine, Sapporo, Japan.
Sawada
K
K
Ieko
M
M
Tarumi
T
T
Koizumi
K
K
Fukada
Y
Y
Sato
N
N
Yasukouchi
T
T
Koike
T
T
D000293:Adolescent; D000328:Adult; D001777:Blood Coagulation; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D005342:Fibrinolysis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000503:physiopathology / Q000628:therapy*; D008099:Liver / Q000201:enzymology; D008228:Lymphoma, Non-Hodgkin / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000503:physiopathology / Q000628:therapy*; D012709:Serum Albumin / Q000032:analysis; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
D012709:Serum Albumin; D002097:C-Reactive Protein